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Alexander W Schüttelkopf2, Simone Belshaw2, Andrew Pannifer2,3, Mairi Sime2, Justin Bower2, Martin Drysdale2
and Michael F Olson1*Abstract
Background: The myotonic dystrophy kinase-related CDC42-binding kinases MRCKα and MRCKβ regulate actin-myosin
contractility and have been implicated in cancer metastasis. Along with the related ROCK1 and ROCK2 kinases, the MRCK
proteins initiate signalling events that lead to contractile force generation which powers cancer cell motility and invasion.
A potential strategy for cancer therapy is to reduce metastasis by blocking MRCK activity, either alone or in
combination with ROCK inhibition. However, to date no potent small molecule inhibitors have been developed
with selectivity towards MRCK.
Results: Screening a kinase-focused small molecule chemical library resulted in the identification of compounds
with inhibitory activity towards MRCK. Medicinal chemistry combined with in vitro enzyme profiling led to the
discovery of 4-chloro-1-(4-piperidyl)-N-[5-(2-pyridyl)-1H-pyrazol-4-yl]pyrazole-3-carboxamide (BDP00005290;
abbreviated as BDP5290) as a potent MRCK inhibitor. X-ray crystallography of the MRCKβ kinase domain in
complex with BDP5290 revealed how this ligand interacts with the nucleotide binding pocket. BDP5290
demonstrated marked selectivity for MRCKβ over ROCK1 or ROCK2 for inhibition of myosin II light chain (MLC)
phosphorylation in cells. While BDP5290 was able to block MLC phosphorylation at both cytoplasmic actin
stress fibres and peripheral cortical actin bundles, the ROCK selective inhibitor Y27632 primarily reduced MLC
phosphorylation on stress fibres. BDP5290 was also more effective at reducing MDA-MB-231 breast cancer cell
invasion through Matrigel than Y27632. Finally, the ability of human SCC12 squamous cell carcinoma cells to
invade a three-dimensional collagen matrix was strongly inhibited by 2 μM BDP5290 but not the identical
concentration of Y27632, despite equivalent inhibition of MLC phosphorylation.
Conclusions: BDP5290 is a potent MRCK inhibitor with activity in cells, resulting in reduced MLC phosphorylation,
cell motility and tumour cell invasion. The discovery of this compound will enable further investigations into the
biological activities of MRCK proteins and their contributions to cancer progression.Background
Tumour cell invasion is a defining hallmark of malignancy
[1]. For most types of solid tumours, patient mortality and
much morbidity is attributable to metastatic disease, of
which invasion is an obligatory component process.
Current anticancer drugs mainly target tumour growth,
and their clinical benefits at all stages of the disease typic-
ally are modest. By subduing cancer cell invasion, particu-
larly in an adjuvant setting, molecularly-targeted inhibitors* Correspondence: m.olson@beatson.gla.ac.uk
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article, unless otherwise stated.that blocked key invasion drivers would be expected to
provide clinical benefit to a significant range of cancer pa-
tients with solid tumours at various stages.
Metastasis is a multi-step process powered by dynamic
reorganization of the actin-myosin cytoskeleton and re-
modelling of the extracellular matrix, allowing cells to
invade their local environment, cross tissue boundaries
and spread via blood and lymphatic vessels to distal
regions of the body [2]. Contraction of actin-myosin
cytoskeletal structures generates the mechanical force
required for cell motility and invasion [2]. A key elem-
ent of the cytoskeletal contractile machinery is myosin
II, which is regulated by phosphorylation of myosin IItral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Ser19) [3].
Members of the RhoGTPase family are central regula-
tors of the actin-myosin cytoskeleton and have been
shown to contribute to multiple processes associated
with invasion and metastasis [2]. Cdc42 signals through
effector proteins including the myotonic dystrophy
kinase-related Cdc42-binding kinases α and β (MRCKα
and MRCKβ), which are 190 kDa multi-domain proteins
with ~80% amino acid identity across their kinase do-
mains, that are expressed in a wide range of tissues [4].
MRCK and the Rho-regulated ROCK kinases belong to
the AGC kinase family [5], and share ~45-50% amino
acid identity in their N-terminal kinase domains, which is
reflected in their shared abilities to phosphorylate a similar
set of substrates including MLC and the inhibitory phos-
phorylation of the myosin binding subunit (MYPT1) of
the MLC phosphatase complex [6]. However, MRCK
and ROCK kinases may phosphorylate substrates, such
as MLC, at different subcellular localizations due to
their specific interactions with targeting proteins and/or
lipids [7-10].
Importantly, it has been observed that the actin-myosin
contractility required for the invasion of three-dimensional
extracellular protein matrices by MDA-MB-231 breast can-
cer cells [6,11] and for the collective invasion of squamous
cell carcinoma (SCC) cells through three dimensional colla-
gen matrices in an organotypic model [12] were dependent
on MRCK signalling. Elevated MRCKα expression was
reported to contribute to Ras oncogene-driven SCC
development in genetically-modified mice following
repression of the Notch1 tumour suppressor [13]. In
addition, gene expression analysis identified MRCKα as
part of a breast cancer gene expression signature linked to
poor patient prognosis and increased incidence of metas-
tasis under five years [14]. These observations indicate
that MRCK contributes to tumour cell invasiveness and
may be an important driver of metastasis.
To date, there have been no potent and selective
MRCK inhibitors reported that could be used to test the
hypothesis that pharmacological inhibition of MRCK ac-
tivity would reduce cancer cell invasion [4]. We now
show that a 2-pyridyl pyrazole amide compound we dis-
covered is a potent MRCK inhibitor with significant
selectivity over the closely-related ROCK kinases both
in vitro and in cells. Determination of the structure of
the MRCKβ kinase domain associated with the com-
pound reveals similarities to ADP in the way that it
is associated with the nucleotide binding pocket. Treat-
ment of MDA-MB-231 human breast cancer cells with
BDP00005290 (BDP5290) was sufficient to fully inhibit
MLC phosphorylation (pMLC) by targeting both cyto-
plasmic and peripheral actin-myosin bundles, in contrast
to the ROCK selective inhibitor Y27632 that preferentiallyreduced cytoplasmic pMLC. Paralleling this observation,
MDA-MB-231 cell invasion through Matrigel was more
efficiently blocked by BDP5290 than Y27632. Invasion of
SCC12 human squamous cell carcinoma into three-
dimensional collagen matrices was strongly inhibited by
BDP5290 but not Y27632, consistent with a previous re-
port that MRCK, and not ROCK, was required for collect-
ive invasion by these tumour cells [12]. These results show
that we have discovered a potent MRCK inhibitor that ef-
fectively blocks tumour cell invasion.
Results and discussion
MRCK inhibitor discovery
After having established an in vitro fluorescence
polarization-based MRCKβ kinase assay [11], a high-
throughput screening campaign of 87,225 compounds was
completed. There were 616 initial compound hits, which
inhibited MRCKβ > 48% when screened at 30 μM (0.7%
hit-rate). Of these, 492 compounds were selected for fur-
ther evaluation and development. A screening cascade
was designed to enable rapid and efficient identification of
MRCK selective inhibitors. Iterative rounds of structure-
activity relationship (SAR) chemistry on representatives of
the initial screening hit matter, in vitro profiling and X-ray
crystallography resulted in the discovery of 4-chloro-1-
(4-piperidyl)-N-[5-(2-pyridyl)-1H-pyrazol-4-yl]pyrazole-3-
carboxamide (BDP5290; Figure 1A) as an MRCK inhibitor
with excellent potency and selectivity profiles. Synthesis
route and methods for BDP5290 will be described in a
subsequent manuscript (in preparation). Inhibitor dose–
response assays at 1 μM ATP, which was close to the
experimentally-determined Km ATP values for the test ki-
nases under the conditions of the enzyme assay (MRCKα,
0.9 μM; MRCKβ, 0.4 μM; ROCK1, 0.6 μM; ROCK2,
0.6 μM), revealed IC50 values of 17 nM for MRCKβ,
230 nM for ROCK1 and 123 nM for ROCK2 (Figure 1B).
Ligand efficiency of BDP5290 was calculated to be 0.40
for MRCKβ [15]. Using the Cheng-Prusoff equation [16]
and the experimentally-determined Km ATP values, the
calculated Ki values revealed 86 and 46-fold in vitro select-
ivity for MRCKβ over ROCK1 and ROCK2, respectively.
The Ki of BDP5290 for MRCKα was 10 nM, which was
slightly more than the Ki of 4 nM for MRCKβ. For com-
parison purposes, at 1 μM ATP the ROCK inhibitor
Y27632 had in vitro IC50 values of 1.45 μM for MRCKβ
and 91 nM for ROCK1 and ROCK2, which indicates lower
on-target potency compared to BDP5290 and only 16-fold
selectivity for ROCK kinases over MRCKβ (Figure 1C).
Additional physicochemical properties of BDP5290 are
listed in Table 1.
Kinase selectivity was determined by measuring the re-
sidual activity in the presence of 10 μM BDP5290 of a
panel of 36 kinases. The results of this screening were
mapped over the annotated human kinome phylogenetic
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Figure 1 Structure of BDP5290 and in vitro kinase inhibition profiles. (A) Structure of 4-chloro-1-(4-piperidyl)-N-[5-(2-pyridyl)-1H-pyrazol-4-yl]
pyrazole-3-carboxamide (BDP5290). (B) BDP5290 dose–response curves for inhibition of MRCKβ, ROCK1 and ROCK2 kinase activity in vitro at 1 μM
ATP. (C) Y27632 dose–response curves for inhibition of MRCKβ, ROCK1 and ROCK2 kinase activity in vitro at 1 μM ATP. All results are shown as
mean ± standard error of n ≥ 4 independent replicates.
Unbekandt et al. Cell Communication and Signaling 2014, 12:54 Page 3 of 15
http://www.biosignaling.com/content/12/1/54tree [17] using Kinome Render [18] (Figure 2). Overall,
the selectivity profile revealed that most kinases were
unaffected by BDP5290 (green labels), with the AGC
family kinases PRK2 and PKAα as well as the CAMK
kinase PhKγ2 being the only ones inhibited >75% (red
circles) at this concentration. These results show that
BDP5290 is a potent MRCK inhibitor suitable as a
chemical biology tool to characterize the contribution
made by MRCK to cancer cell invasion.
Structure of the MRCKβ-BDP5290 complex
To better understand ligand binding to MRCK, we de-
termined the crystal structures of MRCKβ in complex
with ADP to 1.73 Å, as well as with BDP5290 to 1.71 Å
(Figure 3). Both structures adopted overall similar proteinTable 1 Properties of BDP5290
Caco-2 Apical to Basolateral Efflux Ratio 233
Papp (× 10−6 cm s−1) 0.171
Polar surface area (Å2) 100.5
logD 0.786conformations to that we previously reported for MRCKβ
[11], with RMSD values ≤ 1.25 Å after superposition
on ≈ 380 Cα atoms.
The conformation of the MRCKβ kinase domain in
complex with ADP resembled the previously reported
complexes with fasudil or TPCA-1 [11], with the activa-
tion loop open and all important active site features or-
dered. The only significant difference in conformation
around the active site is that the glycine-rich loop is
moved out of the binding site by up to 4 Å to make
space for the diphosphate moiety in the ADP complex.
The nucleotide binds in the conformation typically ob-
served for Ser/Thr protein kinases (Figure 3A). The ad-
enine sits in a mostly hydrophobic pocket formed by the
side chains of Ile82, Val90, Ala103, Tyr155, Tyr156,
Leu207 and Phe370, while also making characteristic
hydrogen bonding interactions with the hinge backbone
(Asp154 carbonyl and Tyr156 amine). Additionally, the
adenine N7 accepts a hydrogen bond from a water mol-
ecule that is part of a small buried water cluster (which
we refer to as “pocket waters”) interacting with Glu124,
Thr137, Asp218 and Phe219. The same water also
hydrogen bonds to the α-phosphate of the nucleotide.
Figure 2 Selectivity profile of BDP5290. The percentage inhibition of 36 kinases by 10 μM BDP5290 was mapped onto the kinome phylogenetic
tree. Kinases inhibited less than 25% have their names in green text. Kinases inhibited >25% and ≤50% have yellow circles, >50% and ≤75% have
orange circles, and >75% have red circles. In each case, the size of the circle is proportional to the percentage inhibition. ROCK1 and MRCKα positions
are indicated on the tree for orientation purposes. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
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from a hydrogen bond to the backbone carbonyl of
Asp204 (C-terminal of the catalytic loop) and a second
hydrogen bond to a surface water that in turn also coor-
dinates the diphosphate. The diphosphate is positioned
by direct and indirect interactions with the side chains
of Asn205 mediated by water molecules or stabilizing
Mg2+ ions, as well as Asp218 of the DFG motif.
Bound BDP5290 (Figures 1A and 3B) fills a similar space
in the MRCKβ active site as that occupied by either fasudilor TPCA-1 [11]. As a consequence, the glycine-rich loop
adopts the closed conformation seen in the other inhibitor
complexes. The pyridine-side pyrazole acts as the hinge
binder, forming hydrogen bonds with the backbone of
Asp154 and Tyr156. The pyridine moiety extends into
space otherwise occupied by the Phe370 side chain.
BDP5290 binding displaces the loop from Asn369 on-
wards and causes the Phe370 side chain to rotate by 120°.
Considering that these residues are directly N-terminal
of an extended loop that is disordered in all MRCKβ
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Figure 3 Structure of MRCKβ in complex with ADP and BDP5290. Stereo views of the MRCKβ active site in complex with ADP (A) or
BDP5290 (B). The ligands are shown in cyan and purple, respectively. Protein residues are coloured grey and labelled. Mg2+ ions are shown as
light green spheres, selected water molecules are indicated by red spheres. Dotted black lines represent potential hydrogen bonding interactions.
|Fo|-|Fc|, φc electron density maps calculated prior to the initial inclusion of the ligands in their respective models are shown contoured at 2.6σ.
This figure was created using PyMOL.
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ible in the ADP complex based on electron density quality,
it is plausible that the BDP5290-induced conformational
change does not carry an extensive energetic penalty. At
the same time, it is noteworthy that the corresponding re-
gion of ROCK1 appears completely ordered [19], thus the
requirement of BDP5290 for conformational change may
contribute to its MRCK selectivity over ROCK kinases.
The pyrazole amide of BDP5290 displaces one of the three
pocket waters, with the ligand carbonyl taking its place
and accepting a hydrogen bond from one of the other two
waters (Figure 3B). The chloropyrazole moiety occupies
space not filled by either fasudil or TPCA-1 without mak-
ing any obvious directional interactions with the protein,
though it is possible that the positioning of the chlorinewith its σ-hole pointing towards the Glu124 side chain
and its partially negatively charged rim interacting with
the side chain amine of Lys105 as well as the backbone
NH of Asp218 makes a contribution to ligand affinity. The
piperidine of BDP5290 (Figure 3B) occupies approximately
the same space as the fasudil piperazine [11]. It packs
against the amide plane between Arg84 and Gly85, but
otherwise points towards solvent.
MRCK inhibition in cells
To determine whether the inhibitor BDP5290 would in-
hibit MRCK in cells, we established cell lines expressing
doxycycline-inducible ROCK1, ROCK2 or MRCKβ kinases
domains that led to increased pMLC following doxycycline
treatment for 18 hours (Figure 4A). By treating cells in
AB D
C E
Figure 4 Inhibition of kinase activity by BDP5290 in cells. (A) MDA-MB-231 breast cancer cells expressing doxycycline inducible ROCK1,
ROCK2 or MRCKβ kinase domains were established as indicated. Following treatment with doxycycline for 18 hours to induce expression, cell
lysates were western blotted with antibodies as indicated. (B) Cells expressing doxycycline-induced MRCKβ, ROCK1 or ROCK2 kinases domains
were treated with BDP5290 at indicated concentrations for 60 minutes prior to lysis and quantitative western blotting. (C) Inhibition of MLC
phosphorylation by BDP5290 for each induced kinase domain. (D) Cells expressing doxycycline-induced MRCKβ, ROCK1 or ROCK2 kinases
domains were treated with Y27632 at indicated concentrations for 60 minutes prior to lysis and quantitative western blotting. (E) Inhibition of
MLC phosphorylation by Y27632 for each induced kinase domain. All results are shown as mean ± standard error of n = 4 independent replicates.
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doxycycline with varying concentrations of BDP5290 from
0 to 3 μM (Figure 4B), cell based EC50 values were de-
termined to be 166 nM for MRCKβ, 501 nM for ROCK1
and 447 nM for ROCK2 (Figure 4C). Interestingly,
3 μM BDP5290 completely inhibited MLC phosphorylationinduced by MRCKβ, but not by ROCK1 or ROCK2. For
comparison, similar experiments were performed with
the ROCK selective inhibitor Y27632 [20] with concen-
trations ranging from 0 to 30 μM (Figure 4D). Inhib-
ition of MLC phosphorylation induced by ROCK1 had
an EC50 value of 4.27 μM and for ROCK2 was 1.62 μM
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MRCKβ activity, inhibition was not greater than 50% at
the highest 30 μM concentration. These results demon-
strate that BDP5290 is a potent inhibitor of MLC phos-
phorylation in cells with selectivity for MRCK over
ROCK1 or ROCK2.
To determine how inhibition of endogenous MRCK
and ROCK affected pMLC levels, we treated parental
MDA-MB-231 breast cancer cells with BDP5290 or
Y27632 at varying concentrations (Figure 5A). BDP5290
had an EC50 of 316 nM while Y27632 was slightly less
potent with an EC50 of 407 nM (Figure 5B). At higher
concentrations, BDP5290 reduced pMLC to undetectable
levels while Y27632 was unable to completely inhibit pMLC
on western blots. Immunofluorescence microscopy of
MDA-MB-231 cells revealed both cytoplasmic stress-fibre
associated and cortical pMLC (Figure 5C). Treatment
for 30 minutes with inhibitors at concentrations near
their EC50 on Western blots showed that 0.5 μM
Y27632 effectively reduced stress-fibre associated pMLC
staining but had little effect on cortical pMLC, in agree-
ment with previous reports showing that ROCK principally
phosphorylates cytoplasmic MLC [10]. In contrast, applica-
tion of 0.5 μM BDP5290 lessened both cytoplasmic and
cortical pMLC levels, which is consistent with previous
reports showing that an important site of MRCK function
is at cortical cytoskeletal structures proximal to the plasma
membrane [21,22].
MRCK inhibition reduces tumour cell motility and
invasion
We and others used siRNA to show that MRCK activity
contributes to the ability of MDA-MB-231 human breast
cancer cells to invade three dimensional Matrigel [6,11]
and SCC12 human squamous cell carcinoma cells to in-
vade collagen in an organotypic skin culture model of
invasion [12]. Using a 96-well based Matrigel invasion
assay and measurements determined with an Incucyte
live content imaging instrument at time points up to 24 h
(Figure 6A), we found that BDP5290 reduced MDA-
MB-231 invasion at all tested concentrations starting
from 0.1 μM, with virtually complete inhibition at 10 μM
(Figure 6B). In contrast, Y27632 was dramatically less
effective at inhibiting invasion at all concentrations,
(Figure 6C). Comparing the dose–response relationship at
24 h after the start of the experiments, the EC50 for
BDP5290 was 440 nM (Figure 6D), which was similar to
the EC50 for inhibiting MLC phosphorylation (Figure 5B).
However, Y27632 inhibition of invasion was not greater
than 50% even at 30 μM (Figure 6D). To ensure that
BDP5290 did not affect MDA MB 231 cell viability, a
range of BDP5290 concentrations were tested for their
effects on metabolic activity relative to DMSO vehicle
using Alamar Blue [23]. After 24 hours in the presenceof BDP5290 cell viability as measured by Alamar Blue
metabolism was slightly reduced with an EC50 > 10 μM
(Figure 6E). Wound closure was inhibited by > 60% at
1 μM BDP5290 (Figure 6D), a concentration that had no
effect on cell viability (Figure 6E), indicating that the
MRCK inhibitor can directly block cell motility independ-
ent of effects on cell proliferation. Treatment with 10 μM
Y27632 had no effect on cell viability (Figure 6E) but
inhibited wound closure by ~40%, indicating that ROCK
inhibition also reduced cell motility directly. Given that
both inhibitors had similar effects on total MLC phos-
phorylation (Figure 5A and B) but their effects on pMLC
in different cellular compartments varied (Figure 5C), one
possibility is that the phosphorylation of cortical MLC is
an important contributor to cell motility and invasion.
Previous studies found that polarized cell motility was
dependent on recruitment of MRCK to the leading edge
[22], where it promotes actin-myosin retrograde flow to
generate tractive forces for cell movement [9]. One mech-
anism identified for this recruitment is the translocation
of MRCKα associated with the PDK1 kinase that binds
membrane phosphatidylinositol (3,4,5)-trisphosphate [24].
Blocking this translocation impairs the ability of MRCKα
to promote lamellipodia retraction with consequent inhib-
ition of directional migration. In addition, MRCK was
found to be required for the assembly of matrix degrading
complexes containing MT1-MMP [25] and promote
cathepsin B expression [26] to permit cell invasion via
matrix degradation. Therefore, BDP5290 may also affect
matrix degradation as well as cell motility, resulting in sig-
nificant inhibition of invasion.
In an organotypic invasion model, the ability of SCC12
cells to collectively invade through physical tracks made
by carcinoma associated fibroblasts (CAF) in three-
dimensional collagen matrices was found to be dependent
on MRCK, and not ROCK [12]. When the effects of vary-
ing doses of BDP5290 and Y27632 on phosphorylated
MLC in SCC12 cells were compared (Figure 7A), both
inhibitors were found to have similar potencies, although
Y27632 showed residual phosphorylated MLC at higher
doses (Figure 7B) as was the case in MDA-MB-231 breast
cancer cells (Figure 5B). To ensure that MRCK or ROCK
inhibition did not affect SCC12 cell viability, DMSO
vehicle, 2 μM BDP5290 or 2 μM Y27632 were tested
for their effects on metabolic activity using Alamar Blue
[23]. After 24 hours in the presence of 2 μM BDP5290 or
2 μM Y27632, cell viability as measured by Alamar Blue
metabolism did not differ from DMSO standard values
(Figure 7C). In addition, when equal numbers of cells were
plated in DMSO vehicle, 2 μM BDP5290 or 2 μM Y27632,
cell confluence as determined by Incucyte image analysis
did not significantly differ between treatments (Figure 7D).
Therefore, neither drug affected SCC12 cell viability or
proliferation. Following CAF-conditioning of the collagen
A B
C
Figure 5 Inhibition of myosin light chain phosphorylation in MDA-MB-231 breast cancer cells by BDP5290. (A) MDA-MB-231 human
breast cancer cells were treated with indicated concentrations of BDP5290 or Y27632 for 30 minutes prior to cell lysis and quantitative western
blotting with indicated antibodies. (B) Inhibition of MLC phosphorylation by BDP5290 and Y27632. All results are shown as mean ± standard error
of n = 3 independent replicates. (C) Immunofluorescence imaging of MDA-MB-231 cells that were untreated or treated with 0.5 μM Y27632 or
BDP5290 for 30 minutes. After fixation and permeabilization, cells were stained with phalloidin to visualize filamentous actin structures and pMLC
(S19) primary antibody as indicated.
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with puromycin, SCC12 cells were layered on the surface
of the protein matrix, the collagen plug was raised above
the air-medium interface and carcinoma cell invasion oc-
curred over ten days in the presence of DMSO vehicle,
2 μM Y27632 or 2 μM BDP5290 as indicated (Figure 7E).Consistent with previous observations [12], ROCK inhib-
ition did not significantly affect SCC12 invasion into the
three dimensional collagen matrix (Figures 7E and F).
However, 2 μM BDP5290 had a profound effect on SCC12
invasion (Figures 7E and F). These data indicate that
MRCK inhibition induces phenotypic responses consistent
AB C
D E
Figure 6 Matrigel invasion of MDA-MB-231 cells is inhibited by BDP5290. (A) MDA-MB-231 human breast cancer cells were plated in 96 well
plates, then 24 hours later a ~800 μm scratch wound was created. Matrigel was overlayed for 1 hour, then images were acquired after 0 and
24 hours in the presence of DMSO vehicle or 3 μM BDP5290. (B) Relative wound closure of MDA-MB-231 cells imaged up to 24 hours at 3 hour
intervals in the presence of indicated BDP5290 concentrations. (C) Relative wound closure of MDA-MB-231 cells imaged up to 24 hours at 3 hour
intervals in the presence of indicated Y27632 concentrations. (D) Relative wound closure of MDA-MB-231 cells at 24 hours in the presence of
indicated BDP5290 or Y27632 doses. All results are shown as mean ± standard error of n ≥ 4 independent replicates. (E) Alamar Blue metabolism
of MDA MB 231 cells after 24 hours in the presence of DMSO vehicle, indicated concentrations of BDP5290 or 10 μM Y27632. Readings were
compared to the Alamar Blue metabolism in DMSO treated cells that were used as the viability standard of 100% for each replicate experiment.
All results are shown as mean ± standard error of 3 independent replicates.
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knockdown of MRCK [12], which validates its use as a tool
compound to explore the contributions of MRCK to
tumour cell invasion and metastasis.Conclusions
In this study we report the discovery of BDP5290, a po-
tent small molecule inhibitor with marked selectivity for
the MRCK kinases. Although the MRCK and ROCK
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ERK2
0 0.5 1 2 5
BDP5290 ( M)
0.5 1 2 5
Y27632 ( M)
BA
C
DMSO 2 m Y27632 2 m BDP5290
D
F
100 m
E
MW
(kDa)
25
55
15
40
DM
SO
Y2
76
32
BD
P5
29
0
0
50
100
150
p<0.05
p<0.05
Nu
m
be
r
o
fi
n
v
ad
in
g
ce
lls
DM
SO
BD
P5
29
0
Y2
76
32
0
50
100
150
200
Re
la
tiv
e
ce
ll
co
n
flu
en
ce
BDP5290 Y27632
0
20
40
60
80
100
Ce
ll
vi
ab
ili
ty
(%
)
-6.5 -6.0 -5.5 -5.0
0
25
50
75
100
Drug concentration (log M)
R
el
at
iv
e
M
LC
ph
os
ph
or
yl
at
io
n
BDP5290
Y27632
Figure 7 Organotypic collagen invasion of SCC12 cells is inhibited by BDP5290. (A) SCC12 human squamous cell carcinoma cells were
treated with indicated concentrations of BDP5290 or Y27632 for 30 minutes prior to cell lysis and quantitative western blotting with indicated
antibodies. (B) Inhibition of MLC phosphorylation by BDP5290 and Y27632. All results are shown as mean ± standard error of n = 3 independent
replicates. (C) Alamar Blue metabolism of SCC12 cells after 24 hours in the presence of DMSO vehicle, 2 μM BDP5290 or 2 μM Y27632. Readings
were compared to the Alamar Blue metabolism in DMSO treated cells that were used as the viability standard of 100% for each replicate
experiment. (D) Percentage cell confluence of 35,000 cells (set to 100% at t = 0) plated in replicate wells of 96 well plates in the presence of
DMSO vehicle, 2 μM BDP5290 or 2 μM Y27632 was determined after 21 hours by imaging with an Incucyte Zoom. (E) Example images of SCC12
cells invading collagen, that had been conditioned by cancer associated fibroblasts for five days prior to their removal, in the presence of DMSO
vehicle 2 μM BDP5290 or 2 μM Y27632 for 10 days. (F) Number of invading cells was determined in 5 random fields for each condition for each
separate replicate experiment. All results are shown as mean ± standard error of n≥ 3 independent replicates.
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revealed some features that contribute to inhibitor se-
lectivity. An intriguing feature of the MRCKβ · BDP5290complex is the presence of the two pocket waters that
are enveloped by the protein and ligand (Figure 3B).
These waters may contribute to MRCK selectivity; the
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ROCK1 likely means that the outer water (on the left
side in Figure 3B) is absent in ROCK1. This is supported
by the available ROCK1 crystal structures, all of which
show either only the inner water or no waters at all in this
pocket (the latter presumably due to the low resolution of
the structures). As a consequence, a ligand that interacts
favourably with the outer water (e.g. BDP5290) should
favour binding to MRCKβ over ROCK1. On the other
hand, the ROCK selective inhibitor fasudil displaces the
outer water without replacing its interactions [11], making
it a poor MRCKβ ligand while not affecting ROCK1 bind-
ing. Therefore, it may be possible to increase ligand potency
by improving interactions with these solvent molecules or
by replacing them appropriately.
In comparison to the widely-used ROCK selective in-
hibitor Y27632, BDP5290 was more effective at reducing
MLC phosphorylation at cortical actin-myosin structures
(Figure 5C), consistent with the reported site of MRCK
action being proximal to plasma membranes. In two
models of tumour cell invasion, BDP5290 was much
more effective than Y27632 at reducing invasiveness
(Figures 6 and 7). It had been previously reported that
invasion by MDA-MB-231 breast cancer cells was partially
inhibited by ROCK or MRCK inhibition/knockdown, but
that full block of invasion required inhibition of both
pathways [6,11]. One possible interpretation of these re-
sults is that the two kinase families act in concert through
independent and non-compensatory mechanisms. Given
that BDP5290 is MRCK selective but with some inhibitory
effect on ROCK activity while Y27632 is predominantly
ROCK selective, the greater effectiveness of BDP5290 at
blocking MDA-MB-231 invasion may be the result of this
dual kinase targeting. The observation that BDP5290
completely blocks MLC phosphorylation is consistent
with it being a dual MRCK/ROCK inhibitor, while the re-
sidual MLC phosphorylation in Y27632 treated cells may
reflect its inability to effectively inhibit MRCK in cells.
Given that BDP5290 and Y27632 were similar in their
potencies for inhibiting MLC phosphorylation and yet
were markedly different in their ability to block tumour
cell invasion, an alternative possibility is that inhibition of
cortical MLC phosphorylation is of greater importance
than cytoplasmic MLC. In the case of SCC12 invasion, the
absolute dependence on MRCK was linked to MLC phos-
phorylation around the periphery of the cell collective [12].
It is also possible that the actions of MRCK proximal to the
plasma membrane lead to phosphorylation of additional
substrates that contribute to invasion, which are less likely
to be regulated by more cytoplasmic ROCK proteins. For
example, MRCK was found to be important for assembly of
matrix degrading complexes containing the transmembrane
MT1-MMP metalloproteinase, which may reflect its actions
near the plasma membrane [25].Proteins that might contribute to cancer are often
identified on the basis of changes in gene expression or
mutations. If MRCK were important in promoting
tumour invasion and metastasis, it would be predicted
that signalling through this pathway would be increased
in metastatic tumour cells. MRCKα (designated PK428
in this study) expression was found to be elevated in
breast tumours, being part of a “poor prognosis” gene
expression signature with increased incidence of distant
metastases in less than 5 years [14]. Consistent with
these observations, increased MRCKα gene copy number
was detected in 542 of 852 (64%) breast cancer samples
at the Wellcome Trust Sanger Institute Cancer Genome
Project (https://www.sanger.ac.uk/research/projects/
cancergenome/). In addition, the activity of the upstream
regulatory Cdc42 protein might be elevated in tumours
by a number of possible mechanisms including; increased
expression, changed activity of positive or negative regula-
tory proteins, or by increased stimulation from extracellu-
lar signals in the tumour microenvironment. Rather than
relying on expression levels as surrogate markers for
activity, reagents that reported on MRCK activity would
be valuable to identify cancers in which this signalling
pathway is activated. In addition, these reagents would
have the potential to be useful as pharmacodynamic
markers of in vivo drug effects. This approach has been
used for ROCK1 and ROCK2, where autophosphorylation
on Ser1333 and Ser1366 respectively were determined to
reflect activity [27,28]. In the case of ROCK2, phospho-
selective antibodies against this Ser1366 post-translational
modification were used to stain breast cancer clinical sam-
ples to detect ROCK2 activation.
Despite the apparent importance of MRCK as a regu-
lator of actomyosin contractility, there is significantly
less known about them than for ROCK. One important
reason for the breadth of knowledge about ROCK func-
tion is because of the discovery of ROCK selective inhib-
itors such as Y27632, which was first published in 1997
[20]. The ready availability of Y27632 and subsequently
improved inhibitors has facilitated research into ROCK
in numerous disease indications. To date, few inhibitors
that affect MRCK activity have been reported. Cheler-
ythrine was first identified as a Protein Kinase C inhibi-
tor with in vitro IC50 of 660 nM [29], and subsequently
was reported to inhibit MRCKα with an in vitro IC50 of
1.77 μM [30]. MRCKα inhibition by chelerythrine was
determined to be through a non-ATP-competitive mech-
anism, but the site of ligand binding has not been deter-
mined. Poor selectivity makes chelerythrine difficult to
use for cell-based experiments to evaluate MRCK function,
additional reported off-target effects include inhibition
of acetylcholinesterases [31], reactive oxygen species
generation [32] and DNA intercalation [33]. The discovery
of inhibitors that potently inhibit MRCK activity will allow
Table 2 Data collection and refinement statistics
ADP complex BDP5290 complex
Wavelength (Å) 0.98 0.97
Space group C2 C2
Cell dimensions a = 114.2 Å; b = 44.0 Å;
c = 91.3 Å; β = 107.4°
a = 115.0 Å; b = 44.0 Å;
c = 91.1 Å; β = 107.3°
Resolution (Å) 26.50–1.73 (1.78–1.73) 40.00–1.71 (1.75–1.71)
Total reflections 143025 (9319) 197075 (15104)
Unique reflections 44725 (3283) 046470 (3438)
Completeness (%) 98.8 (99.2) 98.0 (98.7)
Redundancy 3.2 (2.8) 4.2 (4.4)
I/σ(I) 11.5 (2.2) 12.7 (2.1)
Rmerge 0.047 (0.554) 0.066 (0.571)
Rwork /Rfree 0.196/0.243 0.205/0.236
r.m.s.d. from ideal
geometry:
Bond lengths (Å) 0.013 0.017
Bond angles (°) 1.70 1.69
Average B values:
Overall (Å2) 30.4 29.0
Protein (Å2) 30.0 28.8
Solvent (Å2) 35.7 32.2
Ligand (Å2) 36.2 23.3
PDB ID 4UAK 4UAL
Values in parentheses pertain to the highest resolution shell of ≈ 0.05 Å.
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therapeutic value of MRCK targeting for disease treat-
ments to be determined.
Methods
Kinase assays
MRCKα, MRCKβ, ROCK1 and ROCK2 assays were per-
formed using an IMAP fluorescence polarization assay
format (Molecular Devices Inc.). 8–12 nM of each kin-
ase (Life Technologies) was incubated for 60 min at
room temperature with 100 nM FAM-S6-ribosomal pro-
tein derived peptide (synthesized by Alta Biosciences,
University of Birmingham UK) in the presence of 1 μM
ATP and 0.5 mM MgCl2 in 20 mM Tris buffer (pH 7.4)
containing 0.01% Tween-20 and 1 mM DTT (MRCKα
and β); or 1 μM ATP, 10 mM MgCl2 in 20 mM Tris buf-
fer (pH 7.5) containing 0.25 mM EGTA 0.01% Triton
X-100 and 1 mM DTT (ROCK1 and ROCK2). Typically,
dose response analyses were performed over concentra-
tion ranges from 0.005 - 100 μM. Reactions were
stopped by adding 2 assay volumes of 0.25% (v/v) IMAP
binding reagent in 1× IMAP binding buffer A (Molecu-
lar Devices). After 30 min incubation to allow binding
reagent to bind phosphorylated peptide, fluorescence
polarization was measured on a Tecan Saphire2 plate
reader at excitation (470 nm) and emission (530 nm)
wavelengths. Inhibition was calculated using no inhibitor
and no enzyme controls as 0 and 100% inhibition, re-
spectively. Kinase selectivity profiling was performed by
Eurofins with 10 μM ATP and 10 μM BDP5290.
Protein expression and crystallization
The kinase domain of human MRCKβ (residues 2–417)
was expressed and crystallized as described previously
[11]. Crystals of the MRCKβ BDP5290 complex were
obtained by addition of 0.15 μl of compound stock
(10 mM in DMSO) to a 1.8 μl drop containing ligand-
free crystals for 24 h before cryoprotection in mother
liquor supplemented with 20% ethylene glycol and
data collection.
Data collection, processing, structure solution and
refinement
Data for both ADP-bound protein and the BDP5290
complex were collected at beamline I24 of Diamond
Light Source (Didcot, UK). They were processed and
scaled using XDS [34] to a resolution of ≈ 1.70 Å. Phases
were obtained by molecular replacement using MOLREP
[35] with a protein monomer from the MRCKβ · fasudil
complex (PDB ID 3TKU; [11]) as the search model. Re-
finement proceeded through cycles of model building in
Coot [36] and refinement with PHENIX (ADP complex;
[37]) or REFMAC (BDP5290 complex; [38]); restraints
and starting coordinates for BDP5290 were generatedusing PRODRG [39]. The quality of the final structures
was assessed using Coot and PROCHECK [40]. Data col-
lection and refinement statistics are shown in Table 2.
Cell culture
MDA-MB-231 D3H2LN-Luc cells (Caliper LifeScience)
were grown in MEM/EBSS (Hyclone) supplemented with
10% fetal bovine serum (FBS) (Gibco), 1 mM Sodium Pyru-
vate (Sigma) 2 mM L-glutamine (Gibco), 1× MEM non-
essential amino acids (Gibco) plus penicillin-streptomycin
(10 Units/ml and 10 μg/ml respectively) at 37°C in 5% CO2
in a humidified incubator. MDA-MB-231 D3H2LN-Luc
TetOn MRCKβ, ROCK1 and ROCK2 selective cell lines
were grown in the same media with 10% FBS replaced with
10% Tet System Approved FBS (Clontech).
HN-CAF cells (a gift from Erik Sahai, Cancer Research
UK London Institute) were grown in DMEM (Gibco,
21969–035) with 10% fetal bovine serum (FBS) (Gibco,
10270), 2 mM L-glutamine (Gibco, 25030–032) at 37°C in
5% CO2 in a humidified incubator. SCC12 cells (a gift
from Erik Sahai) were grown in 2/3 DMEM, 1/3 Ham’s
nutrient F12 (Gibco, 21765–029), 2 mM L-glutamine, 10%
FBS, 5 μg insulin (Sigma, I0516), 10 ng/mL EGF (Sigma,
E9644) and 0.5 μg/ml hydrocortisone (Sigma, H-0135).
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MDA-MB-231 D3H2LN-Luc cells stably expressing the
Tet-On 3G (Tet3G) transactivator (Clontech) were gen-
erated according to the manufacturer’s instructions.
Briefly, MDA-MB-231 D3H2LN-Luc cells were trans-
fected with pCMV-Tet3G (Clontech) using Xfect trans-
fection reagent (Clontech) and selected with G418
(600 μg/ml). G418-resistant colonies were isolated, ex-
panded, and Tet3G transactivator expression determined
by western blot analysis using the TetR antibody (Clon-
tech). Clonal cell lines expressing the Tet3G protein
were transfected with pTRE3G-Luc reporter construct,
treated with and without doxycycline (1 μg/ml), and lu-
ciferase activity determined. The clone exhibiting the
lowest basal activity and greatest doxycycline induction
was used to generate the Tet-On inducible cell lines de-
scribed below.
The kinase domains of MRCKβ (1–473), ROCK1 (1–535)
or ROCK2 (1–532) were gene synthesized (Genscript) and
subcloned into pTRE3G (Clontech). MDA-MB-231
D3H2LN-Luc Tet3G cells were co-transfected with
pTRE3G-MRCKβ (1–473), pTRE3G-ROCK1 (1–535) or
pTRE3G-ROCK2 (1–532), together with a linear Purr-
selection marker using Xfect transfection reagent ac-
cording to manufacturer’s instructions. Following selection
in puromycin (0.5 μg/ml), single colonies were isolated and
expanded. Each clone was treated with or without doxycyc-
line (1 μg/ml) for 24 hours and kinase domain expression
and activity determined by western blotting. For each
Tet-inducible kinase, clones were chosen which showed ro-
bust inductions of kinase domain expression together with
the highest-fold induction of phospho-MLC2 (Thr18/Ser19)
expression in response to doxycycline treatment.
Cell extraction and immunoblot analysis
Cell lysates were prepared as described previously [41].
For pMLC western blots, cells were lysed in a 1% (w/v)
SDS, 50 mM Tris pH 7.5 buffer and lysates were passed
through QIAshredder columns (Qiagen, 79654). Alterna-
tively, for pMLC western blots lysates were prepared in
lysis buffer with 50 mM Tris (pH7.5), 0.5% (w/v) SDS,
supplemented with Complete Protease and PhosSTOP
inhibitors (Roche). Whole cell lysates were separated by
SDS-PAGE, transferred to Protran nitrocellulose mem-
branes (Whatman), probed with primary antibodies and
appropriate IR dye-conjugated secondary antibodies.
Blots were visualized using a Licor Odyssey according to
manufacturer’s instructions. Antibodies used in this
study were: MRCKα (611584) from BD Transduction
Laboratories; MRCKβ (H00009578-A01) from Abnova;
MRCKα/β (MANDM1 6G8) from Glenn Morris (Centre
for Inherited Neuromuscular Disease, Oswestry UK)
[42,43]; MRCL3/MRLC2/MYL9 (sc-28329) from Santa
Cruz Biotechnology; pMLC2 Thr18/Ser19 (3674) fromCell Signaling Technology. ROCK1/2 (07–1458) from
Millipore; TetR (Clone 9G9; 631132) from Clontech;
α-Tubulin (TU-02; sc-8035) from Santa Cruz Biotech-
nology; ERK2 from Chris Marshall (Institute of Cancer
Research, London UK). Secondary antibodies used were:
goat anti-mouse IgG Dylight 800 from Thermo Scientific
(35521), goat anti rabbit IgG AlexaFluor 680 from Invitrogen
(A12076), goat anti-rabbit IgG IR Dye 800 CW (926–32211)
and goat anti-mouse IgG IR Dye 680 (926–68020) were
from LI-COR Biosciences.Immunofluorescence
MDA-MB 231 cells were grown on glass coverslips in 24
well plates. Cells were treated for 30 minutes with either
DMSO vehicle, 0.5 μM Y27632 (Calbiochem, #688000)
or 0.5 μM BDP5290. Cells were then washed with PBS,
fixed in 4% para-formaldehyde (PFA; EMS #15710) in
PBS for 15 minutes, washed twice in PBS, permeabilized
with 0.5% Triton X100 (Thermo Scientific, #28314) in
PBS for 15 minutes and washed twice in PBS. After
blocking for 30 minutes in PBS with 1% BSA, fixed cells
were incubated with pMLC2 Ser19 antibody (Cell Signaling
Technology, #3675) for 1 hour at room temperature.
Cells were washed three times in PBS with 1% BSA,
and incubated in the dark with secondary antibody
anti-mouse Alexa Fluor 488 (Invitrogen, A11029) and
Texas Red Phalloidin (Invitrogen, T7471) for 1 hour at
room temperature. Cells were washed three times in
PBS with 1% BSA, once in PBS and once in water. Cov-
erslips were mounted with Vectashield (Vector). Slides
were visualized with a Zeiss 710 confocal microscope.
Post-imaging linear adjustments for brightness and
contrast were made uniformly for all image panels to
improve the clarity and discernibility of subcellular
structures.Matrigel invasion assays
MDA-MB-231 cells were plated at 30,000 cells per well in
Image Lock 96 well plates (Essen BioScience) in 100 μL
complete DMEM medium and after allowing cells to settle
for 20 min were incubated overnight at 37°C in 5% CO2 in
a humidified incubator. Matrigel (BD Biosciences) was
thawed overnight at 4°C, diluted 1:1 with PBS and 100 μL
pipetted over cells that had been scratched with the
WoundMaker tool (Essen BioScience). Plates were incu-
bated for 1 h, then appropriately diluted drugs added in
100 μL media to achieve final concentrations. Plates were
scanned with an Incucyte Zoom (Essen BioSciences) ac-
cording to manufacturer’s instructions at 3 hour intervals.
Cell viability was determined with AlamarBlue (Invitrogen,
DAL 1025), which was added to the medium and cells cul-
tured for 6 hours. Absorbances at 570 nm and at 600 nm
were measured to assess metabolic activity.
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SCC12 invasion assays were performed essentially as de-
scribed in [12]. HN-CAF cells were grown for 5 days in
a Matrigel-collagen gel, covered with DMEM+ 10%FBS
medium, and allowed to remodel the matrix. The gel
consisted of: 280 μL of DMEM+ 10% FBS, 100 μL FBS,
20 μL 1 M Hepes pH 7.5 and approximately 200 μL of
Matrigel (BD Biosciences, 354234), 400 μL of collagen
type 1 (BD Biosciences, 354249) and 5×105 HN-CAF
cells. Puromycin was subsequently added to the medium
at 10 μg/ml for 3 days to remove HN-CAF cells. The
gels were washed in SCC medium 3 times for 2 hours
and SCC12 cells were plated on the surface of the gel
and left to adhere overnight. The gels were placed on
nylon filters supported by metal grids and cultured for
10 days at the interface with SCC medium and either
DMSO vehicle, 2 μM Y27632 or 2 μM BDP5290. The
gels were fixed overnight in 4% PFA and 1% glutaralde-
hyde in PBS, washed in PBS and processed for histology.Alamar Blue and confluence analysis
MDA MB 231 or SCC12 cells were plated in a 96 well
plate and cultured for 24 hours. Cells were then cultured
for 24 hours in SCC12 medium with DMSO vehicle,
2 μM Y27632 or indicated concentrations of BDP5290
in an IncuCyte ZOOM (Essen Bioscience). Pictures were
taken every 3 hours and confluence was measured using
the IncuCyte analysis software. AlamarBlue (Invitrogen,
DAL 1025) was added to the medium and the cells were
cultured for an additional day. Absorbances at 570 nm
and at 600 nm were measured to assess cell health.
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